Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2(+) Breast Cancer

HER family members are interdependent and functionally compensatory. Simultaneously targeting EGFR/HER2/HER3 by antibody combinations has demonstrated superior treatment efficacy over targeting one HER receptor. However, antibody combinations have their limitations, with high immunogenicity and high...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiaolin, Ghamande, Sharad, Liu, Haitao, Xue, Lu, Zhao, Shuhua, Tan, Wenxi, Zhao, Lijing, Tang, Shou-Ching, Wu, Daqing, Korkaya, Hasan, Maihle, Nita J., Liu, Hong Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862534/
https://www.ncbi.nlm.nih.gov/pubmed/29499944
http://dx.doi.org/10.1016/j.omtn.2017.12.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862534/
https://www.ncbi.nlm.nih.gov/pubmed/29499944
http://dx.doi.org/10.1016/j.omtn.2017.12.015

Ejemplares similares